Compare PRPO & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRPO | VNRX |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.4M | 38.2M |
| IPO Year | N/A | N/A |
| Metric | PRPO | VNRX |
|---|---|---|
| Price | $23.38 | $0.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.50 |
| AVG Volume (30 Days) | 7.7K | ★ 2.2M |
| Earning Date | 11-14-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $22,800,000.00 | $1,472,007.00 |
| Revenue This Year | N/A | $55.98 |
| Revenue Next Year | N/A | $420.37 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 30.95 | 14.48 |
| 52 Week Low | $3.90 | $0.22 |
| 52 Week High | $28.50 | $0.94 |
| Indicator | PRPO | VNRX |
|---|---|---|
| Relative Strength Index (RSI) | 50.08 | 45.05 |
| Support Level | $22.40 | $0.22 |
| Resistance Level | $24.60 | $0.26 |
| Average True Range (ATR) | 1.32 | 0.02 |
| MACD | -0.20 | 0.01 |
| Stochastic Oscillator | 43.69 | 60.42 |
Precipio Inc is a healthcare solutions company focused on cancer diagnostics. It focuses on addressing the problem of cancer misdiagnoses by developing solutions to mitigate the root causes of this problem in the form of diagnostic products, reagents, and services. The company operates Clinical Laboratory Improvement Amendments laboratories in both the New Haven, Connecticut and Omaha, Nebraska locations providing essential blood cancer diagnostics to office-based oncologists in many states nationwide. It provides new technologies to the oncology diagnostic laboratory market in the form of HemeScreen and IV-Cell product offerings. The company generates the majority of its revenue from third-party payers.
VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.